Rubius Therapeutics to Announce Third Quarter 2021 Financial Results
Rubius Therapeutics (Nasdaq: RUBY) announced that it will release its third quarter financial results on November 8, 2021, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rubius Therapeutics (Nasdaq: RUBY) announced that it will release its third quarter financial results on November 8, 2021, after market close. The company focuses on developing Red Cell Therapeutics™ for treating cancer and autoimmune diseases, leveraging its RED PLATFORM® for engineered red blood cells. Notably, there will be no teleconference following the report. Rubius aims to advance its product candidates using innovative therapeutic modalities, which highlights its commitment to pioneering cellular therapies in the biopharmaceutical space.
Positive
- Upcoming third quarter financial results announcement on November 8, 2021.
Negative
- None.
Details
News Market Reaction – RUBY
The recorded move for RUBY in the trading session of this news was +1.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report third quarter financial results on Monday, November 8, 2021, after market close.
The company will not be hosting a teleconference in conjunction with its financial results press release.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was named among the 2020 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2021 Best Places to Work in Rhode Island by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.
Contacts:
Elhan Webb, CFA
Vice President, Investor Relations
elhan.webb@rubiustx.com
Media:
Marissa Hanify
Director, Corporate Communications
marissa.hanify@rubiustx.com
Dan Budwick
1AB
+1 (973) 271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.